Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOW-OGESTREL-21 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP3A4 isoenzymes (ethinyl estradiol and norgestrel undergo hydroxylation and conjugation). Enterohepatic circulation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norgestrel: 93-95% (albumin, SHBG); ethinyl estradiol: 97-98% (albumin).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norgestrel: 3.5-4.5 L/kg; ethinyl estradiol: 2.5-3.5 L/kg; indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: norgestrel >90%; ethinyl estradiol 40-50% (first-pass metabolism).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dosage adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No data available for fictional drug ALYACEN 777.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Do not use.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults: one tablet daily for 21 days, then 7 days off.
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke, and generally avoided in older women due to increased cardiovascular risk.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke). Risk increases with age (>35 years) and smoking severity. Women over 35 who smoke should not use this drug.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thromboembolic disorders (venous and arterial),Cerebrovascular disease,Myocardial infarction,Hypertension,Hepatic adenoma or carcinoma,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular changes (e.g., retinal thrombosis),Headache/migraine exacerbation,Uterine bleeding irregularities,Fetal development (discontinue if pregnancy suspected),Depression,Contact lens intolerance,Fluid retention,Breast cancer risk (ongoing surveillance),Hereditary angioedema
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Known or suspected pregnancy,Current or history of thrombophlebitis or thromboembolic disorders,Current or history of cerebrovascular or coronary artery disease,Breast cancer or other estrogen-sensitive neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known liver impairment,Major surgery with prolonged immobilization,Diabetes mellitus with vascular involvement,Uncontrolled hypertension,Hypertriglyceridemia,Smoking >15 cigarettes/day and age ≥35,Migraine with focal aura at any age
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure but does not require avoidance. Alcohol does not impair contraceptive efficacy but may increase risk of nausea or missed doses.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester. Second and third trimester exposure may cause masculinization of female fetuses due to progestin component.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Small amounts of ethinyl estradiol and norgestrel are excreted in human milk. M/P ratio not established. May reduce milk production and composition. Use is generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy; no dose adjustments indicated as drug should not be used. Pharmacokinetic changes in pregnancy (e.g., increased clearance) are not relevant due to contraindication.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
LOW-OGESTREL-21 is a low-dose estrogen-progestin combination oral contraceptive. Its effectiveness may be reduced by concomitant enzyme-inducing drugs (e.g., rifampin, carbamazepine, phenytoin, St. John's wort). Breakthrough bleeding and spotting are more common with low-dose formulations. Contraception is not reliable if two or more active pills are missed; backup contraception is required. Initiation on the first day of menstrual bleeding eliminates need for backup contraception. Advise patients to take pill at same time daily to maintain consistent hormone levels.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time, even if you have spotting or bleeding between periods.,If you miss one pill, take it as soon as you remember and continue the next pill at the usual time; no backup is needed.,If you miss two consecutive active pills, take two pills daily for two days, then resume one daily; use backup contraception for 7 days.,Possible side effects include nausea, headache, breast tenderness, and irregular bleeding; these often improve after 3 cycles.,Smoking while using this pill increases risk of serious cardiovascular events; do not smoke if over 35 years old.,Use a backup method (e.g., condoms) until you have taken 7 consecutive active pills if starting for the first time after day 5 of menstrual cycle.,Store pills at room temperature away from moisture.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOW-OGESTREL-21 vs ALYACEN 777, answered by our medical review team.
LOW-OGESTREL-21 is a Oral Contraceptive that works by Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOW-OGESTREL-21 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOW-OGESTREL-21 is: One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOW-OGESTREL-21 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOW-OGESTREL-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester.. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.